TGFβ, TGFβ receptors, Ki-67, and p27Kip1 expression in papillary thyroid carcinomas

Endocrine Pathology

Volumn 8, Issue 4, 1997, Pages 293-300

  Lloyd, Ricardo V ^a   Ferreiro, Jorge A ^a   Jin, Long ^a   Sebo, Tom J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Ki 67; p27; Papillary carcinoma; Thyroid; Transforming growth factor beta

Indexed keywords

EID: 0000552258     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02739931     Document Type: Article

References (30)

1. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. Fascicle 5, Third series. Washington DC: Armed Forces Institute of Pathology, 1992.
2. Livolsi VA. Surgical pathology of the thyroid. Philadelphia: Saunders, 1990.
3. Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleveland Clin Q 43:207-216, 1976.
4. Johnson TL, Lloyd RV, Thompson NW, Beierwalles WH, Sisson JC. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 12:22-27, 1988.
5. Terry JH, St. John SA, Karkowski FJ, Suarez JR, Vassa NH, Platica CD, Marti JR. Tall cell papillary thyroid cancer: incidence and prognosis. Am J Surg 168:459-461, 1994.
6. Vickery AL, Carcangiu ML, Johannessen JV. Papillary carcinoma. Semin Diagn Pathol 2:90-100, 1985.
7. Evans HL. Columnar-cell carcinoma of the thyroid: a report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol 85:77-80, 1986.
8. Sobrinho-Simoes M, Neslanid JM, Johannessen JV. Columnar-cell carcinoma: another variant of poorly differentiated carcinoma of the thyroid. Am J Clin Pathol 89:264-267, 1988.
9. Ferreiro JA, Hay ID, Lloyd RV. Columnar cell carcinoma of the thyroid: report of three additional cases. Human Pathol 27:1156-1160, 1996.
10. Carcangiu ML, Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma: clinicopathologic study of 15 cases. Am J Surg Pathol 13:1041-1049, 1985.
11. Fujimoto Y, Obara T, Ito Y, Kodama T, Aiba M, Yamaguchi K. Diffuse sclerosing variant of papillary carcinoma of the thyroid: clinical importance, surgical treatment, and follow-up study. Cancer 66:2306-2312, 1990.
12. Fagin J, Matsio K, Karmaker A, Chen D, Tang S, Koeffler H. High prevalence of mutations of pS3 gene in poorly differentiated human thyroid carcinomas. Clin Invest 91:179-184, 1993.
13. Carr K, Heffess C, Jin L, Lloyd RV. Immunohistochemical analysis of thyroid carcinomas utilizing antibodies to p53 and Ki-67. Appl Immunohistochem 1:201-207, 1993.
14. Jasini B, Wyllie FS, Wright PP, Lemoine NR, William ED, Wynford-Thomas D. Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors 2:149-155, 1990.
15. Van der Laan BFAM, Freeman JL, Asa SL. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5:67-73, 1995.
16. Ebner R, Chen H, Shum LI, Lawler S, Lee AL, Zioncheck TF, Lopez AR, Derynck R. Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science 260:1334-1348, 1993.
17. Sim L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang X-F, Brattain MG. Expression of transforming growth factor-β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269:26,449-26,455, 1994.
18. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, Sporn MB. Genetic changes in the transforming growth factor-β (TGFb) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGFb. Proc Natl Acad Sci USA 91:8772-8776, 1994.
19. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268:1336-3987, 1996.
20. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmander J, Vellucci VF, Reiss M. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous cell carcinoma cells. Cancer Res 55:3982, 1995
21. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extra-cellular antimitogenic signals. Cell 78:59-66, 1994.
22. Kip1, a cyclin-cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22, 1994.
23. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994.
24. Grubeck-Loeberstein B, Bulhan G, Sadeghi R, Kissonerghis M, Londer M, Turner M, Pirich K, Roka R, Niederle B, Kassal H, Waldhausl W, Feldman M. Transforming growth factor beta regulates thyroid growth rate in the pathogenesis of nontoxic goiter. J Clin Invest 83:764-770, 1989.
25. Holting T, Zielke A, Siperstein AK, Clark DH, Duh Q-Y. Transforming growth factor-β is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion and adhesion of cultured follicular and papillary thyroid cancer cell lines. J Clin Endocrinol Metab 79:806-813, 1994.
26. Forid NR, Shi Y, Zon M. Molecular basis of thyroid cancer. Endocrine Rev 15:202-232, 1994.
27. Kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407, 1997.
28. Evans HL. Encapsulated columnar-cell neoplasm of the thyroid: a report of four cases suggesting a favorable prognosis. Am J Surg Pathol 20:1205-1211, 1996.
29. Ostrowski ML, Merino MJ: Tall cell variant of papillary thyroid carcinoma. A reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964-974, 1966.
30. Flint A, Davenport RD, Lloyd RV. The tall cell variant of papillary carcinoma of the thyroid gland, comparison with the common form of papillary carcinoma by DNA and morphometric analysis. Arch Pathol Lab Med 115:169-171, 1991.